Skip to main content

Table 1 Clinical and Baseline characteristics

From: Low expression of ZHX1 and ZHX2 impacts on the prognosis of chronic lymphocytic leukemia

Characteristics All Patients (%) ZHX 1 p ZHX2 p
Low High Low High
Age, y
Median (range)
65 (43, 85) 65.5 (54, 80) 59 (43, 85) .44 66.5 (54, 80) 59 (43, 85) .15
Sex     .24    .01
 Female 21 (41.1) 9 (34.6) 12 (48)   5 (20.8) 13 (56.5)  
 Male 30 (58.9) 17 (65.4) 13 (52)   19 (79.2) 10 (43.5)  
Binet     .26    .60
 A 35 (68.7) 17 (68) 18 (69.2)   16 (48.5) 17 (51.5)  
 B 11 (21.5) 4 (16) 7 (27)   5 (50) 5 (50)  
 C 5 (9.8) 4 (16) 1 (3.8)   3 (75) 1 (25)  
Platelets     .16    .55
 median (range), X109 /L 142.5 (11, 312) 137.5 (15, 261) 147 (11, 312)   141.5 (15, 312) 140 (11, 284)  
WBC     .03    .15
 median (range), X109 /L 45.2 (7.8, 170.1) 61.1 (29, 170.1) 23.4 (7.8, 93.2)   45.3 (10.5, 170.1) 30.1 (7.8, 93.2)  
ZAP-70a     .18    .37
 Negative 16 (32) 6 (24) 10 (40)   7 (30.4) 9 (39.1)  
 Positive 34 (68) 19 (76) 15 (60)   16 (69.6) 14 (60.9)  
Karyotype     .007    .04
 Normal 12 (23.5) 2 (7.7) 10 (40)   3 (12.5) 9 (39.1)  
 Abnormal 39 (76.5) 24 (92.3) 15 (50)   21 (87.5) 14 (60.1)  
Cytogenetic risk     .002    .09
 Favorable 14 (27.5) 2 (7.7) 12 (48)   4 (16.7) 10 (43.5)  
 Intermediate 20 (39.2) 11 (42.3) 9 (36)   11 (45.8) 9 (39.1)  
 Adverse 17 (33.3) 13 (50) 4 (16)   9 (37.5) 4 (17.4)  
Number of karyotypic changes     .003    .01
 0 12 2 (7.7) 10 (40)   3 (12.5) 9 (39.1)  
 1 or 2 26 13 (50) 13 (52)   13 (54.2) 13 (56.5)  
 3 or more 13 11 (42.3) 2 (8)   8 (33.3) 1 (4.4)  
  1. Values represent number (percentage), or median (range) when indicated in the row headings
  2. a Missing values were excluded for statistical analysis
  3. Statistically significant differences are in bold